RECRUITING

Dupixent and Narrowband UVB for Atopic Dermatitis

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

Official Title

Single Center, Pilot Study to Evaluate the Effectiveness and Safety of Dupilumab in Combination With Narrowband UVB (nUVB) Phototherapy in the Treatment of Moderate-to-Severe Atopic Dermatitis

Quick Facts

Study Start:2022-04-19
Study Completion:2024-12-15
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05285839

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Male or female adult ≥ 18 years of age;
  2. * Diagnosis of moderate to severe atopic dermatitis as defined at baseline by:
  3. * EASI score of 16 or greater,
  4. * IGA score of 3 or greater
  5. * BSA of 10% or greater,
  1. * Subjects with previous exposure to dupilumab.
  2. * Known or suspected hypersensitivity to dupilumab or any of its excipients.
  3. * History of photosensitivity.

Contacts and Locations

Study Contact

Elise Nelson
CONTACT
6094434500
enelson@windsordermatology.com

Study Locations (Sites)

Eczema Treatment Center of New Jersey
East Windsor, New Jersey, 08520
United States

Collaborators and Investigators

Sponsor: Psoriasis Treatment Center of Central New Jersey

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-04-19
Study Completion Date2024-12-15

Study Record Updates

Study Start Date2022-04-19
Study Completion Date2024-12-15

Terms related to this study

Additional Relevant MeSH Terms

  • Atopic Dermatitis